A5019373426- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Parkinson's Disease Mechanisms and Treatments
- Functional Brain Connectivity Studies
- Frailty in Older Adults
- Neurological disorders and treatments
- Neuroscience and Neuropharmacology Research
- Cholinesterase and Neurodegenerative Diseases
- Cerebrovascular and Carotid Artery Diseases
- Advanced Neuroimaging Techniques and Applications
- Neurological and metabolic disorders
- Radiomics and Machine Learning in Medical Imaging
- Neurobiology of Language and Bilingualism
- Neurological Disease Mechanisms and Treatments
- Cerebrospinal fluid and hydrocephalus
- Geriatric Care and Nursing Homes
- Memory and Neural Mechanisms
- Urbanism, Landscape, and Tourism Studies
- Palliative Care and End-of-Life Issues
- Hemispheric Asymmetry in Neuroscience
- Hearing, Cochlea, Tinnitus, Genetics
- Hearing Loss and Rehabilitation
- Medical Image Segmentation Techniques
University of Utah
2015-2024
Nia Association
2022
ID Genomics (United States)
2022
University of Utah Health Care
2021
University of California, San Diego
2009-2019
Texas Neurology
2019
Alzheimer's Association
2011-2019
Utah State University
2019
Huntsman Cancer Institute
2019
Brigham Young University
2019
Abstract This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clinical diagnosis of probable disease is possible, using [ 18 F]fluorodeoxyglucose positron emission tomography. First, 66 patients with spectrum dementia severity (Mini‐Mental State Examination score, 0–23) were recruited and studied. Cortical metabolic activity was analyzed topographically three‐dimensional stereotactic surface projections. Regression analysis performed for each brain...
A Clinical Task Force, composed of clinical leaders from Alzheimer's Disease Centers (ADC), was convened by the National Institute on Aging to develop a uniform set assessment procedures characterize individuals with mild Alzheimer disease and cognitive impairment in comparison nondemented aging. The resulting Uniform Data Set (UDS) defines common observations be collected longitudinally ADC participants accordance standard methods. UDS implemented at all ADCs September 1, 2005. obtained are...
<b>Objective:</b> A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification optimal markers for predicting disease progression remains unresolved. The goal this study was evaluate prognostic ability genetic, CSF, neuroimaging, and obtained same participants. <b>Methods:</b><i>APOE</i> ε4 allele frequency, CSF proteins (Aβ<sub>1-42</sub>, total tau, hyperphosphorylated tau [p-tau<sub>181p</sub>]), glucose metabolism...
Positron emission tomography (PET) of brain amyloid β is a technology that becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association Society Nuclear Medicine Molecular Imaging convened Amyloid Taskforce (AIT). The AIT considered broad range specific scenarios which PET could potentially be used appropriately. Peer‐reviewed, published literature...
Distinguishing Alzheimer's disease (AD) and frontotemporal dementia (FTD) currently relies on a clinical history examination, but positron emission tomography with [(18)F] fluorodeoxyglucose (FDG-PET) shows different patterns of hypometabolism in these disorders that might aid differential diagnosis. Six experts variable FDG-PET experience made independent, forced choice, diagnostic decisions 45 patients pathologically confirmed AD (n = 31) or FTD 14) using five separate methods: (1) review...
Local rates of cortical glucose metabolism were estimated by positron emission tomography in 13 right-handed patients with Alzheimer's disease. Individuals disproportionate failure language function had markedly diminished the left frontal, temporal, and parietal regions. Patients predominant visuo-constructive dysfunction evidenced a hypometabolic focus right cortex. memory as most apparent feature no significant metabolic asymmetry In all subjects, verbal competency generally correlated...
Abstract Seeking antemortem markers to distinguish Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), we examined brain glucose metabolism of DLB AD. Eleven patients (7 body variant AD [LBVAD] 4 pure diffuse [DLBD]) who had position emission tomography imaging autopsy confirmation were compared 10 autopsy‐confirmed patients. In addition, 53 clinically‐diagnosed probable AD, 13 whom later fulfilled clinical diagnoses DLB, examined. Autopsy‐confirmed showed significant metabolic...
Background This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core. Methods The Core has supervised acquisition, quality control, and analysis longitudinal [ 18 F]fluorodeoxyglucose PET (FDG‐PET) data in approximately half ADNI cohort. In an “add on” study, 100 subjects also underwent scanning with 11 C] Pittsburgh compound B for amyloid imaging. developed control procedures standardized image acquisition by developing...
<b>Background:</b> PET imaging using [<sup>18</sup>F]fluorodeoxyglucose (FDG) and [<sup>11</sup>C]Pittsburgh compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), CSF measures the 42 amino acid β-amyloid protein (Aβ<sub>1-42</sub>) total phosphorylated tau (t-tau p-tau). Relationships between with severity are incompletely understood. <b>Methods:</b> Ten subjects AD, 11 control subjects, 34 mild cognitive impairment from Alzheimer’s Disease Neuroimaging Initiative...
Abstract Regional cerebral glucose metabolism, an index of neuronal activity, was compared in 20 patients with Alzheimer's disease and 8 age‐matched normal volunteers by positron emission tomography following { 18 F}2‐fluoro‐2‐deoxy‐D‐glucose administration. Overall cortical utilization the group 10 to 49% below that control individuals. The posterior parietal cortex contiguous portions temporal anterior occipital lobes were most severely affected; frontal relatively spared. This pattern...
Abstract To map presynaptic cholinergic terminal densities in normal aging (n = 36), Alzheimer's disease (AD) 22), and Parkinson's (PD) 15), we performed single‐photon emission computed tomography using [ 123 I]iodoben‐zovesamicol (IBVM), an vivo marker of the vesicular acetylcholine transporter. We used coregistered positron with 18 F]fluorodexyglucose for metabolic assessment magnetic resonance imaging atrophy assessment. In controls (age, 22–91 years), cortical IBVM binding declined only...
To determine whether baseline hearing loss increases cognitive decline and risk for all-cause dementia in a population of elderly individuals.Longitudinal cohort study.Community-based, outpatient.Men women aged 65 years or older without at baseline.All subjects completed the Modified Mini-Mental Status Exam (3MS-R) over 3 triennial follow-up visits. Hearing (HL) was based on observation difficulties during testing interview. Incident determined by clinical assessment expert...
Estimates of incident dementia, and cognitive impairment, not dementia (CIND) (or the related mild impairment) are important for public health clinical care policy. In this paper, we report US national incidence rates CIND.Participants in Aging, Demographic, Memory Study (ADAMS) were evaluated impairment using a comprehensive in-home assessment. A total 456 individuals aged 72 years older, who demented at baseline, followed longitudinally from August 2001 to December 2009. An expert...
Background: Some elderly individuals exhibit significant memory deficits but do not have dementia because their general intellect is preserved and they no impairments in everyday activities.These symptoms are often a precursor to Alzheimer disease (AD), sometimes does occur, even after many years of observation.There currently reliable way distinguish between these 2 possible outcomes an individual patient.We hypothesized that clear at least 1 cognitive domain addition would help identify...
<b><i>Objective:</i></b> To validate an in vivo method for mapping acetylcholinesterase (AChE) activity human brain, preparatory to monitoring inhibitor therapy AD. <b><i>Background:</i></b> AChE is decreased postmortem AD brain. Lacking a reliable measure, little known about central early AD, when the disease commonly targeted by drug therapy. <b><i>Methods:</i></b> Intravenous <i>N</i>-[<sup>11</sup>C]methylpiperidin-4-yl propionate ([<sup>11</sup>C]PMP) served as substrate. was defined...
<b><i>Background:</i></b> Treatment of agitation is a crucial problem in the care patients with AD. Although antipsychotic and antidepressant medications behavior management techniques (BMT) have each been used to treat agitation, clinical trials these treatments characterized by small sample sizes uncontrolled treatment designs. <b><i>Objective:</i></b> To compare haloperidol, trazodone, BMT placebo AD outpatients. <b><i>Methods:</i></b> A total 149 their caregivers participated randomized,...
We studied the clinical features, pathology, and molecular genetics of a family (Mo) with an autosomal dominant disinhibition, frontal lobe dementia, parkinsonism, amyotrophy. examined seven affected members gathered information on another six. The mean onset was at age 45 years. Personality behavioral changes (disinhibition, withdrawal, alcoholism, hyperphagia) were first symptoms in twelve. There early memory loss, anomia, poor construction preservation until late orientation, speech,...